Literature DB >> 30167720

Tight control: a new therapeutic strategy in the management of osteoporotic patients.

A Halasi1, G Kincse2, J Varga3, J Kéri4, J Gaál5,6.   

Abstract

BMD changes in patients under tight control (monitored at 3-month intervals with adjustment of therapy guided by bone turnover markers) and routine management (controlled once a year) were compared. After 1 year, the femoral neck BMD increased significantly in the tight control compared to the routine management group.
INTRODUCTION: We intended to ascertain whether tight control (i.e., follow-up visits and bone turnover markers/BTM/and parathyroid hormone/PTH/monitoring at 3-month intervals) strategy achieves a statistically greater increase in bone mineral density over the observation period than standard follow-up care (i.e., bone densitometry at 1-year intervals, without BTM monitoring).
METHODS: We studied involutional osteoporotic patients newly enrolled into chronic care. One hundred and eleven patients underwent tight control, while another 113 received routine treatment (with follow-up visits scheduled at > 1-year intervals). We compared the changes in bone mineral density reflected by the results of bone mineral density (BMD) measurements of the lumbar spine and of the left femoral neck. Statistical analyses were performed with version 22 of the SPSS software package.
RESULTS: In the group of patients under tight control, baseline and follow-up median BMD values were 0.842/0.881 g/cm2 at the L1-4 vertebrae and 0.745/0.749 g/cm2 at the femoral neck. In the group under routine care, the corresponding values were 0.903/0.915 g/cm2 and 0.742/0.72 g/cm2, respectively. The relative changes of the bone mineral density of the femoral neck was significantly (p = 0.041) higher in patients under tight control than in those receiving routine care; however, BMD changes in the lumbar spine were not statistically different.
CONCLUSION: Our findings suggest that adopting tight control as a new therapeutic strategy might be justified in the osteoporosis management. In fact, a greater improvement of BMD can be achieved by treatment according to these principles.

Entities:  

Keywords:  Osteoporosis; Strategy; Tight control; Treatment

Mesh:

Substances:

Year:  2018        PMID: 30167720     DOI: 10.1007/s00198-018-4674-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  27 in total

1.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 2.  The assessment of bone metabolism in vivo using biochemical approaches.

Authors:  R G Russell
Journal:  Horm Metab Res       Date:  1997-03       Impact factor: 2.936

Review 3.  Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?

Authors:  Jean-Pierre Devogelaer; Yves Boutsen; Damien Gruson; Daniel Manicourt
Journal:  Rheum Dis Clin North Am       Date:  2011-08       Impact factor: 2.670

4.  Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.

Authors:  Sang Wan Kim; Do Joon Park; Kyong Soo Park; Seong Yeon Kim; Bo Youn Cho; Hong Kyu Lee; Chan Soo Shin
Journal:  Endocr J       Date:  2005-12       Impact factor: 2.349

5.  Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.

Authors:  Jean-Yves Reginster; Julien Collette; Audrey Neuprez; Brigitte Zegels; Rita Deroisy; Olivier Bruyere
Journal:  Bone       Date:  2008-02-15       Impact factor: 4.398

Review 6.  Osteoporosis prevention, diagnosis, and therapy.

Authors: 
Journal:  JAMA       Date:  2001-02-14       Impact factor: 56.272

7.  The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

Authors:  Jackie A Clowes; Nicola F A Peel; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

Review 8.  Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.

Authors:  Anthony I Sebba
Journal:  Clin Ther       Date:  2008-03       Impact factor: 3.393

Review 9.  Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis.

Authors:  Jehoon Lee; Samuel Vasikaran
Journal:  Ann Lab Med       Date:  2012-02-23       Impact factor: 3.464

Review 10.  Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  P Bergmann; J-J Body; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; J-Y Reginster; V Gangji
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.